1. Open-Label Phase III Trial of Panitumumab Plus Best Supportive Care Compared With Best Supportive Care Alone in Patients With Chemotherapy-Refractory Metastatic Colorectal Cancer
2. Colon cancer: ESMO Clinical Recommendations for diagnosis, adjuvant treatment and follow-up
3. Hecht J, Mitchell E, Chidiac Tet al.An updated analysis of safety and efficacy of oxaliplatin (Ox)/bevacizumab (bev) +/- panitumumab (pmab) for first-line treatment (tx) of metastatic colorectal cancer (mCRC) from a randomized, controlled trial (PACCE). In:Gastrointestinal Cancers Symposium. FL, USA, 25–27 January 2008.
4. Hecht J, Mitchell E, Chidiac Tet al.Interim results from PACCE: Irinotecan (Iri)/bevacizumab (bev) ± panitumumab (pmab) as first-line treatment (tx) for metastatic colorectal cancer (mCRC). In:Gastrointestinal Cancers Symposium.FL, USA, 25–27 January 2008.
5. Phase III study (PRIME/20050203) of panitumumab (pmab) with FOLFOX compared with FOLFOX alone in patients (pts) with previously untreated metastatic colorectal cancer (mCRC): Pooled safety data